{"id":"W4387809604","doi":"10.1016/j.annonc.2023.10.053","title":"LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"National Institutes of Health; European Society for Medical Oncology; BeiGene; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Chemotherapy; Complete response; Pathological; Clinical endpoint; Phases of clinical research; Neoadjuvant therapy; Immunotherapy; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001237438,0.000614965,0.001234818,0.0002298019,0.0002880262,0.001193333,0.0004534418,0.0005813659,0.00350134],"category_scores_gemma":[0.0008627064,0.0002767816,0.001434588,0.0002499617,0.0004624131,0.0006406146,0.0003040067,0.001600955,0.0007892114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008396883,"about_ca_system_score_gemma":0.0009881279,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001552771,"about_ca_topic_score_gemma":0.003832859,"domain_scores_codex":[0.9996582,0.0001269547,0.00001541756,0.00007631122,0.00003487065,0.00008818712],"domain_scores_gemma":[0.9994215,0.0001579462,0.0001020241,0.00008905405,0.00004175316,0.0001879072],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7796889,0.007908546,0.05969584,0.000587465,0.003278923,0.0001122666,0.0001645575,0.002528593,0.02595976,0.0004543601,0.006625168,0.1129956],"study_design_scores_gemma":[0.2918221,0.3092831,0.3482957,0.0002898062,0.008599421,0.0005983834,0.000304058,0.006703741,0.01511867,0.001388987,0.01745046,0.0001455339],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928202,0.002503222,0.0002816677,0.00023229,0.00009587895,0.0002321804,0.001422225,0.00005514384,0.002357107],"genre_scores_gemma":[0.9919494,0.000812721,0.0005457649,0.0005681065,0.00006394314,0.0003307415,0.003050171,0.0000399917,0.002639096],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00350134,"threshold_uncertainty_score":0.01171309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07998844053475229,"score_gpt":0.4265823777995135,"score_spread":0.3465939372647612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}